Research Insights on Medulloblastoma - Pipeline Review, H1 2016

Medulloblastoma - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Medulloblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

To access full report with TOC, please visit ​Medulloblastoma - Pipeline Review, H1 2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
- The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Medulloblastoma therapeutics and enlists all their major and minor projects
- The report assesses Medulloblastoma therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Medulloblastoma

Reasons to buy

- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Bayer AG DelMar Pharmaceuticals, Inc. Ignyta, Inc. Lipocure Ltd. MacroGenics, Inc. Medicenna Therapeutics, Inc. MEI Pharma, Inc. Novartis AG Novogen Limited Progenics Pharmaceuticals, Inc. Stemline Therapeutics, Inc. Takeda Pharmaceutical Company Limited

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###